Related Experiment Videos
Acute tubular necrosis after interleukin-2 therapy
1Department of Internal Medicine, Texas Tech University Medical Center, Lubbock 79430.
The Central African Journal of Medicine
|September 1, 1993
Summary
Metastatic renal cell cancer immunotherapy using interleukin-2 (IL2) can cause kidney damage. Prompt treatment with fluids and medication reversed the renal tubular necrosis, restoring normal kidney function.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Metastatic renal cell cancer (mRCC) treatment increasingly involves immunotherapy.
- Interferon and interleukin-2 (IL2) are common immunotherapeutic agents for mRCC.
- Potential adverse events, including renal complications, require careful monitoring.